Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).

× No keyword cloud information.

9 in total

1. Respiratory syncytial virus: pervasive yet evasive.

Authors: Erica Weir; David N Fisman
Journal: CMAJ Date: 2004-01-20 Impact factor: 8.262

2. Respiratory syncytial virus and palivizumab: Where are we in 2014?

Authors: Joan Robinson
Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471

3. Respiratory infections in children up to two years of age on prophylaxis with palivizumab.

Authors: Ana Isabel M P Monteiro; Nancy Cristina J Bellei; Alessandra Ramos Sousa; Amélia Miyashiro N dos Santos; Lily Yin Weckx
Journal: Rev Paul Pediatr Date: 2014-06

4. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.

Authors: Hayat Caidi; Congrong Miao; Natalie J Thornburg; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal: Antiviral Res Date: 2018-04-17 Impact factor: 5.970

5. Prophylaxis of respiratory syncytial virus in Canada in 2003.

Authors: Joan L Robinson; Bonita E Lee
Journal: Paediatr Child Health Date: 2003-12 Impact factor: 2.253

6. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Authors: Andrew Warren; Joanne M Langley; Wanda Thomas; Jeff Scott
Journal: Can J Cardiol Date: 2007-05-01 Impact factor: 5.223

7. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

Authors: Marc Bellavance; Charles V Rohlicek; Jean-Luc Bigras; Jean-Marc Côté; Marc Paquet; Marc H Lebel; Andrew S Mackie
Journal: Paediatr Child Health Date: 2006-01 Impact factor: 2.253

8. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005).

Authors: T M Berger; C Aebi; A Duppenthaler; M Stocker
Journal: Infection Date: 2008-12-09 Impact factor: 3.553

9. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.

Authors: Kecia N Carroll; Tebeb Gebretsadik; Gabriel J Escobar; Pingsheng Wu; Sherian Xu Li; Eileen M Walsh; Ed Mitchel; Chantel D Sloan; William D Dupont; Tina V Hartert
Journal: J Allergy Clin Immunol Date: 2016-04-21 Impact factor: 10.793

9 in total